Drugs in the Pipeline
The IMbrave050 study included 662 patients with HCC at high risk for recurrence after surgical resection or ablation with curative intent.
News
The approval was based on data from the SORAYA trial.
Drug Monograph Updates
The summary below gives an overview of important additions and changes MPR has made to its drug database through the end of October. The chart below provides highlights of key monograph updates made this month (not an inclusive list). Click on the name of the drugs to view the full monographs on eMPR.com. Key: D=Dosing,…
Drug Monograph
Bevacizumab 100mg, 400mg; per vial; soln for IV infusion after dilution; preservative-free.
Select the therapeutic use below to view the corresponding drug monograph
Visit the related Resource Center for drug monographs, news, CME and other clinical tools for this drugs’ particular therapeutic area.
Drug Monograph
Bevacizumab-maly 100mg, 400mg; per vial; soln for IV infusion after dilution; preservative-free.
Select the therapeutic use below to view the corresponding drug monograph
Visit the related Resource Center for drug monographs, news, CME and other clinical tools for this drugs’ particular therapeutic area.
News
Alymsys is a vascular endothelial growth factor inhibitor.
News
Vegzelma is a vascular endothelial growth factor inhibitor.
Drugs in the Pipeline
Mirvetuximab soravtansine is an antibody-drug conjugate comprised of a FRα-binding antibody, a cleavable linker, and a potent tubulin-targeting agent.